Ultragenyx Gene Therapy Becomes First FDA-Approved Treatment for Ultra-Rare Disease
Frank Vinluan / medcitynews - Ultragenyx Pharmaceutical’s Genglycos received accelerated FDA approval for glycogen storage disease type Ia, an inherited enzyme deficiency. It’s also the first approved gene therapy for Ultragenyx, which specializes in rare disease treatments. The post …
AI Summary: Ultragenyx received FDA approval for a gene therapy, marking the first approved treatment for that particular ultra‑rare disorder. The decision provides a regulated therapeutic option for patients previously without approved care, highlighting the evolving regulatory willingness to greenlight transformative but small‑population medicines.
Related Stories
FDA escalates push to withdraw Amgen’s Tavneos; Amgen updates label / 3 months
Personalized genetic therapy yields improvements in children with rare epilepsy / 5 wks
Single‑infusion gene editing dramatically lowers LDL cholesterol in early trial / 2 months
Prediction markets wager on drug trials, raising research integrity concerns / 4 wks
US gray‑market peptides face scrutiny as FDA panel debate looms / 1 month
FDA clears first targeted therapy for ultra-rare NRG1-driven cholangiocarcinoma / 3 months
FDA approves first drug treating full spectrum of narcolepsy symptoms / 22 days
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Alzheimer's disease, FDA, Novo Nordisk, Healthcare and look for the RSS link.
StackHealth Time Machine